Limited impact of prenatal COVID-19 exposure on child neurodevelopmental outcomes

Research shows prenatal exposure to SARS-CoV-2 linked to slight regulatory behavior improvements in infants, but no significant neurodevelopmental impacts.

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 19, 2024

Senolytics show promise in combating brain aging and COVID-19 neuropathology

Study reveals that senolytics can reduce aging in human brain organoids and mitigate COVID-19 neuropathology, suggesting their potential as a therapeutic strategy against brain aging

November 15, 2023

Metabolic syndrome risk found to be five times higher in males than in females

Risk of metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke and Type 2 diabetes, doubled in people during the

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.